Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine
SH Hohnloser,
A van de Loo,
and
F Baedeker
Department of Cardiology, University Hospital, Freiburg, Germany.
OBJECTIVES. This study compared the efficacy and safety of sotalol and quinidine for conversion and prevention of recurrent atrial fibrillation. BACKGROUND. Atrial fibrillation is the most common arrhythmia. Pharmacologic therapy has been advocated for both immediate restoration of sinus rhythm and prevention of recurrent atrial fibrillation. Quinidine is the therapeutic mainstay for both purposes, but its safety has recently been questioned. Although sotalol has been used successfully to maintain sinus rhythm after direct current cardioversion, its efficacy in pharmacologically reverting atrial fibrillation has not been examined. METHODS. Fifty consecutive patients with persistent atrial fibrillation were randomized to receive quinidine or sotalol for up to 7 days to restore sinus rhythm. Patients were followed up for 6 months. RESULTS. Quinidine was more effective than sotalol in terminating atrial fibrillation (60% vs. 20%, p = 0.009). When nonresponders to drug therapy underwent subsequent direct current cardioversion, total conversion rates in the quinidine and sotalol groups were comparable (88% vs. 68%, p = 0.17), as was the efficacy of the two drugs in preventing recurrent atrial fibrillation. Side effects necessitating drug discontinuation were more often observed with quinidine. No patient receiving sotalol but four patients receiving quinidine had drug-associated arrhythmia (torsade de pointes in three patients, sustained ventricular tachycardia in one patient). Precordial QT dispersion determined on the surface electrocardiogram (ECG) increased with quinidine (mean +/- SD 34 +/- 9 vs. 44 +/- 16 ms, p = 0.02), indicating enhanced inhomogeneity in ventricular repolarization. There was no change in QT dispersion in patients receiving sotalol (36 +/- 18 vs. 40 +/- 17 ms, p = 0.44). CONCLUSIONS. Quinidine is more effective than sotalol in terminating atrial fibrillation but is associated with more side effects. The proarrhythmic risk may be related to quinidine's propensity to increase disparity in ventricular repolarization. This risk warrants careful ECG monitoring during the 1st 4 to 7 days of therapy. Because most proarrhythmic effects occurred shortly after restoration of sinus rhythm, observation should continue > or = 2 to 3 days after sinus rhythm is reestablished.
This article has been cited by other articles:
|
|
|
|
 
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst
CHAPTER 29 Atrial Fibrillation
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace,
September 1, 2006;
8(9):
651 - 745.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
854 - 906.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
e149 - e246.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
e257 - e354.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
700 - 752.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Eur. Heart J.,
August 2, 2006;
27(16):
1979 - 2030.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lafuente-Lafuente, S. Mouly, M. A. Longas-Tejero, I. Mahe, and J.-F. Bergmann
Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.
Arch Intern Med,
April 10, 2006;
166(7):
719 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. McNamara, L. J. Tamariz, J. B. Segal, and E. B. Bass
Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography
Ann Intern Med,
December 16, 2003;
139(12):
1018 - 1033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Nichol, F McAlister, B Pham, A Laupacis, B Shea, M Green, A Tang, and G Wells
Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation
Heart,
June 1, 2002;
87(6):
535 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
Circulation,
October 23, 2001;
104(17):
2118 - 2150.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
Eur. Heart J.,
October 2, 2001;
22(20):
1852 - 1923.
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
J. Am. Coll. Cardiol.,
October 1, 2001;
38(4):
1231 - 1265.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.H. Veloso
Effects of oral sotalol administration before electrical cardioversion of persistent atrial fibrillation
Eur. Heart J.,
August 2, 2001;
22(16):
1512 - 1514.
[PDF]
|
|
|
|
|
|
|
M. Frick
A reply
Eur. Heart J.,
August 2, 2001;
22(16):
1513 - 1514.
[PDF]
|
|
|
|
|
|
|
K. Derakhchan, C. Villemaire, M. Talajic, and S. Nattel
The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF
Cardiovasc Res,
April 1, 2001;
50(1):
75 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Malik and V. N. Batchvarov
Measurement, interpretation and clinical potential of QT dispersion
J. Am. Coll. Cardiol.,
November 15, 2000;
36(6):
1749 - 1766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W Haverkamp, G Breithardt, A.J Camm, M.J Janse, M.R Rosen, C Antzelevitch, D Escande, M Franz, M Malik, A Moss, et al.
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology
Eur. Heart J.,
August 1, 2000;
21(15):
1216 - 1231.
[PDF]
|
|
|
|
|
|
|
W. Haverkamp, G. Breithardt, A.J. Camm, M. J Janse, M. R Rosen, C. Antzelevitch, D. Escande, M. Franz, M. Malik, A. Moss, et al.
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications: Report on a Policy Conference of the European Society of Cardiology
Cardiovasc Res,
August 1, 2000;
47(2):
219 - 233.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Frick, B. Darpo, J. Ostergren, and M. Rosenqvist
The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation
Eur. Heart J.,
July 2, 2000;
21(14):
1177 - 1185.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. M. Gillis, H. J. Mathison, E. Kulisz, and W. M. Lester
Dispersion of Ventricular Repolarization and Ventricular Fibrillation in Left Ventricular Hypertrophy: Influence of Selective Potassium Channel Blockers
J. Pharmacol. Exp. Ther.,
January 1, 2000;
292(1):
381 - 386.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. Houltz, B. Darpo, K. Swedberg, P. Blomstrom, H.J.G.M. Crijns, S.M. Jensen, E. Svernhage, and N. Edvardsson
Comparison of QT dispersion during atrial fibrillation and sinus rhythm in the same patients, at normal and prolonged ventricular repolarization
Europace,
January 1, 2000;
2(1):
20 - 31.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Yesil, S. Bayata, N. Postaci, O. Yucel, O. Aslan, and S. Bayata
Cardioversion with Sotalol in Selected Patients with Vagally and Adrenergically Mediated Paroxysmal Atrial Fibrillation
Angiology,
September 1, 1999;
50(9):
729 - 733.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. M. J. Choy, D. Darbar, S. Dell'Orto, and D. M. Roden
Exaggerated QT prolongation after cardioversion of atrial fibrillation
J. Am. Coll. Cardiol.,
August 1, 1999;
34(2):
396 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-P. Lau, H.-F. Tse, and G. M. Ayers
Defibrillation-guided radiofrequency ablation of atrial fibrillation secondary to an atrial focus
J. Am. Coll. Cardiol.,
April 1, 1999;
33(5):
1217 - 1226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. E. Kochiadakis, N. E. Igoumenidis, F. I. Parthenakis, G. I. Chlouverakis, and P. E. Vardas
Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study
J. Am. Coll. Cardiol.,
March 15, 1999;
33(4):
966 - 971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Eckman, R. H. Falk, and S. G. Pauker
Cost-effectiveness of Therapies for Patients With Nonvalvular Atrial Fibrillation
Arch Intern Med,
August 10, 1998;
158(15):
1669 - 1677.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. A. Grace and A. J. Camm
Quinidine
N. Engl. J. Med.,
January 1, 1998;
338(1):
35 - 45.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-G. Li and S. H. Hohnloser
Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 1998;
3(2):
185 - 194.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Yamashita, Y. Murakawa, K. Sezaki, M. Inoue, N. Hayami, Y. Shuzui, and M. Omata
Circadian Variation of Paroxysmal Atrial Fibrillation
Circulation,
September 2, 1997;
96(5):
1537 - 1541.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. S. Stambler, M. A. Wood, K. A. Ellenbogen, K. T. Perry, L. K. Wakefield, and J. T. VanderLugt
Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation
Circulation,
October 1, 1996;
94(7):
1613 - 1621.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Quinidine vs. Sotalol for Atrial Fibrillation
Journal Watch Cardiology,
December 1, 1995;
1995(1201):
9 - 9.
[Full Text]
|
|
|
|
|
|
|
QUINIDINE VS. SOTALOL FOR ATRIAL FIBRILLATION
Journal Watch (General),
October 13, 1995;
1995(1013):
5 - 5.
[Full Text]
|
|
|
|
